Cyclophosphamide-asparaginase-vincristine-prednisone induction therapy in childhood acute lymphocytic and nonlymphocytic leukemia
- 1 March 1976
- Vol. 37 (3) , 1243-1247
- https://doi.org/10.1002/1097-0142(197603)37:3<1243::aid-cncr2820370303>3.0.co;2-6
Abstract
A remission-induction regimen for childhood leukemia using cyclophosphamide, asparaginase, vincristine, and prednisone (CAVP) was compared to standard vincristine-prednisone (VP) induction. The more intensive regimen was associated with a lower complete remission rate (81% vs 93%) and a higher early death rate from infection (15% vs 5%) for acute lymphocytic leukemia. In contrast, complete remission was achieved in 58% of children with acute nonlymphocytic leukemia treated with CAVP compared to 18% for VP. Early death rates were similar (27% vs 25%). These observations corroborate previous studies in childhood nonlymphocytic leukemia showing activity for asparaginase. Preliminary analysis of remission duration and survival for responders shows no advantage for those who survived the more intensive induction.This publication has 6 references indexed in Scilit:
- Long-term results of reinforcement therapy in children with acute leukemiaCancer, 1975
- Combination chemotherapy with cytosine arabinoside and rubidomycin in 30 cases of acute granulocytic leukemiaCancer, 1973
- L-asparaginase therapy in children with advanced leukemiaThe Southwest cancer chemotherapy study groupCancer, 1971
- Therapy of acute leukemia with drug combinations which include asparaginaseCancer, 1971
- Prolonged infusion of arabinosyl cytosine in childhood leukemiaCancer, 1970
- A generalized Wilcoxon test for comparing arbitrarily singly-censored samplesBiometrika, 1965